Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Thomssen C, Vetter M, Kantelhardt EJ, Meisner C, Schmidt M, Martin PM, Clatot F, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jänicke F, Loibl S, Minckwitz GV, Harbeck N; NNBC 3-Europe Study Group. Thomssen C, et al. Among authors: vetter m. Cancers (Basel). 2023 Mar 3;15(5):1580. doi: 10.3390/cancers15051580. Cancers (Basel). 2023. PMID: 36900372 Free PMC article.
Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer.
Harbeck N, Schmitt M, Vetter M, Krol J, Paepke D, Uhlig M, Paepke S, Jänicke F, Geurts-Moespot A, von Minckwitz G, Sweep F, Thomssen C. Harbeck N, et al. Among authors: vetter m. Breast Care (Basel). 2008;3(s2):11-15. doi: 10.1159/000151734. Epub 2008 Oct 16. Breast Care (Basel). 2008. PMID: 20824008 Free PMC article. No abstract available.
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N. Kantelhardt EJ, et al. Among authors: vetter m. BMC Cancer. 2011 Apr 16;11:140. doi: 10.1186/1471-2407-11-140. BMC Cancer. 2011. PMID: 21496284 Free PMC article. Clinical Trial.
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Jacobs VR, Kates RE, Kantelhardt E, Vetter M, Wuerstlein R, Fischer T, Schmitt M, Jaenicke F, Untch M, Thomssen C, Harbeck N. Jacobs VR, et al. Among authors: vetter m. Breast Cancer Res Treat. 2013 Apr;138(3):839-50. doi: 10.1007/s10549-013-2496-z. Epub 2013 Apr 9. Breast Cancer Res Treat. 2013. PMID: 23568480 Clinical Trial.
The prevalence of estrogen receptor-negative breast cancer in Ethiopia.
Kantelhardt EJ, Mathewos A, Aynalem A, Wondemagegnehu T, Jemal A, Vetter M, Knauf E, Reeler A, Bogale S, Thomssen C, Stang A, Gemechu T, Trocchi P, Yonas B. Kantelhardt EJ, et al. Among authors: vetter m. BMC Cancer. 2014 Nov 29;14:895. doi: 10.1186/1471-2407-14-895. BMC Cancer. 2014. PMID: 25433805 Free PMC article.
Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S, Bayerlová M, Vetter M, Wachter A, Mitra D, Hanf V, Lantzsch T, Uleer C, Peschel S, John J, Buchmann J, Weigert E, Bürrig KF, Thomssen C, Korf U, Beissbarth T, Wiemann S, Kantelhardt EJ. Bernhardt S, et al. Among authors: vetter m. Breast Cancer Res. 2017 Oct 11;19(1):112. doi: 10.1186/s13058-017-0905-7. Breast Cancer Res. 2017. PMID: 29020998 Free PMC article. Clinical Trial.
426 results